MDT

87.66

-0.88%↓

VEEV

280.9

-1.16%↓

A

119.22

-1.87%↓

WBA

11.53

+0.52%↑

HQY

101.41

-0.54%↓

MDT

87.66

-0.88%↓

VEEV

280.9

-1.16%↓

A

119.22

-1.87%↓

WBA

11.53

+0.52%↑

HQY

101.41

-0.54%↓

MDT

87.66

-0.88%↓

VEEV

280.9

-1.16%↓

A

119.22

-1.87%↓

WBA

11.53

+0.52%↑

HQY

101.41

-0.54%↓

MDT

87.66

-0.88%↓

VEEV

280.9

-1.16%↓

A

119.22

-1.87%↓

WBA

11.53

+0.52%↑

HQY

101.41

-0.54%↓

MDT

87.66

-0.88%↓

VEEV

280.9

-1.16%↓

A

119.22

-1.87%↓

WBA

11.53

+0.52%↑

HQY

101.41

-0.54%↓

Search

BioCryst Pharmaceuticals Inc

Cerrado

SectorSalud

8.75 -1.91

Resumen

Variación precio

24h

Actual

Mínimo

8.71

Máximo

8.95

Métricas clave

By Trading Economics

Ingresos

27M

32K

Ventas

14M

146M

BPA

0

Margen de beneficio

0.022

Empleados

580

EBITDA

22M

21M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+87.36% upside

Dividendos

By Dow Jones

Próximas Ganancias

4 ago 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

23M

1.9B

Apertura anterior

10.66

Cierre anterior

8.75

Noticias sobre sentimiento de mercado

By Acuity

9%

91%

6 / 375 Clasificación en Healthcare

BioCryst Pharmaceuticals Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

7 jul 2025, 15:29 UTC

Principales Movimientos del Mercado

Mustang Bio Shares Jump After Orphan Drug Designation for Cancer Treatment

7 jul 2025, 23:44 UTC

Charlas de Mercado

Nikkei May Fall on U.S. Tariff Concerns -- Market Talk

7 jul 2025, 23:44 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

7 jul 2025, 23:41 UTC

Charlas de Mercado

Gold Edges Lower Amid Hopes for Possible Trade Agreements -- Market Talk

7 jul 2025, 23:19 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

7 jul 2025, 23:19 UTC

Charlas de Mercado

AML3D Bull Sees Navy Letter Lowering Risks -- Market Talk

7 jul 2025, 22:20 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

7 jul 2025, 22:20 UTC

Charlas de Mercado

AT&T's Fiber Strategy Positions Stock to Outperform -- Market Talk

7 jul 2025, 21:34 UTC

Adquisiciones, fusiones, absorciones

BlackRock's Latest Acquisition Is a Commercial Real Estate Bet -- Barrons.com

7 jul 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

7 jul 2025, 20:45 UTC

Adquisiciones, fusiones, absorciones

CoreWeave Is Buying Core Scientific. The CEO Explains Why. -- Barrons.com

7 jul 2025, 20:16 UTC

Charlas de Mercado

Canada Bonds Set to Benefit From Rotation Away U.S. Assets -- Market Talk

7 jul 2025, 19:37 UTC

Charlas de Mercado

U.S. Natural Gas Futures Hold Their Ground -- Market Talk

7 jul 2025, 19:12 UTC

Charlas de Mercado

Oil Futures Shrug Off Bigger OPEC+ Output Increase -- Market Talk

7 jul 2025, 18:33 UTC

Charlas de Mercado

Gold Flat as Investors Assess Market Direction -- Market Talk

7 jul 2025, 18:27 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

7 jul 2025, 16:53 UTC

Ganancias

Freight Stocks Have a Tariff Overhang. Morgan Stanley Says It Could Be Worse. -- Barrons.com

7 jul 2025, 16:30 UTC

Charlas de Mercado

Higher Prices Limit Power Sector's Natural Gas Use -- Market Talk

7 jul 2025, 16:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

7 jul 2025, 16:05 UTC

Adquisiciones, fusiones, absorciones

CoreWeave Is Buying Core Scientific. The CEO Explains Why. -- Barrons.com

7 jul 2025, 15:41 UTC

Charlas de Mercado

Gold Futures Fall as Stronger U.S. Dollar Undermines Safe-Haven Demand -- Market Talk

7 jul 2025, 15:41 UTC

Charlas de Mercado

Market Talk Roundup: Latest on U.S. Politics

7 jul 2025, 15:40 UTC

Charlas de Mercado

Base Metal Prices Tick Lower on U.S. Dollar Strength -- Market Talk

7 jul 2025, 15:30 UTC

Charlas de Mercado

Physical Oil Market Stable But Structural Weakness Looms -- Market Talk

7 jul 2025, 15:18 UTC

Charlas de Mercado

BNP Cuts Brent Forecast on U.S. Shale, Iran Supply Resilience -- Market Talk

7 jul 2025, 15:14 UTC

Adquisiciones, fusiones, absorciones

MicroStrategy Goes a Week Without Buying Bitcoin. Saylor Has Advice for Crypto Traders. -- Barrons.com

7 jul 2025, 15:00 UTC

Adquisiciones, fusiones, absorciones

GSK Completes Acquisition of Efimosfermin

7 jul 2025, 14:52 UTC

Charlas de Mercado

Dollar Faces Downward Pressures Stemming from Tariffs -- Market Talk

7 jul 2025, 14:51 UTC

Charlas de Mercado

Bullish Factors Lift Oil Despite Downward Pressure -- Market Talk

7 jul 2025, 14:45 UTC

Charlas de Mercado

Saudi Arabia Not Seeking to Take Oil Market Share -- Market Talk

Comparación entre iguales

Cambio de precio

BioCryst Pharmaceuticals Inc Esperado

Precio Objetivo

By TipRanks

87.36% repunte

Estimación a 12 meses

Media 16.75 USD  87.36%

Máximo 30 USD

Mínimo 11 USD

De acuerdo con 12 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para BioCryst Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

12 ratings

11

Comprar

1

Mantener

0

Vender

Sentimiento

By Acuity

6 / 375 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura alcista notoria

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.